R&D expenses of BioNTech by type 2022-2023
On November 9th 2020, German biotech company BioNTech in cooperation with U.S. pharma giant Pfizer were the first to announce a proven COVID-19 vaccine to be ready for mass production by year-end. In 2023, total R&D expenses of biotech company BioNTech SE stood at some 1.78 billion U.S. dollars, of which nearly 1.5 billion euros were spent on non-COVID-19 products.